CELLSENSE - MICROENGINEERING CELL RESPONSE
The CellSense technology is designed to interfere with the complex biological response involved in the foreign body reaction and subsequent formation of fibrotic tissue around the implantable medical device.
The foreign body response begins with adsorption of various proteins to the surface of the implant. This non-specific layer of proteins labels the device as foreign to the body and triggers high neutrophil activity and release of soluble factors.
Subsequently macrophages and monocyte precursor cells are recruited. Given the impossibility to kill the foreign object, the immune system starts the recruitment of fibroblasts, with the aim of encapsulating the foreign material in a newly deposited collagen matrix. The resulting fibrotic capsule creates a thick physical and physiological barrier between the implant and the host tissue, leading to several clinical problems.
The CellSense technology comprises surface microstructured biosynthesised cellulose which disrupts the process of cell adhesion and deposition of fibrous tissue, through a combination of ideal physiochemical and surface characteristics.
The CellSense technology is the foundation for the Hylomate range of products currently developed for a number of intended uses and indications.
An extensive development program has been undertaken to gather evidence on the safety and performance of the Hylomate range of products. In vitro studies have clearly shown the effectiveness of the technology to reduce cell adhesion to a minimum when compared to other materials and surfaces and further long term in vivo studies have shown a significant reduction of fibrotic encapsulation when combined with a variety of soft tissue implantable medical devices.
Development timeline for the Hylomate range of products incorporating the CellSense technology
 S. Bottan et al., “Surface-structured bacterial cellulose with guided assembly-based biolithography (GAB),” ACS Nano, vol. 9, no. 1, pp. 206–219, 2015.
 F. Robotti et al., “A micron-scale surface topography design reducing cell adhesion to implanted materials,” Sci. Rep., vol. 8, no. 1, p. 10887, Dec. 2018.
 F. Robotti et al, "Microengineered biosynthesized cellulose as anti-ﬁbrotic in vivo protection for cardiac implantable electronic devices," Biomaterials, vol. 229, 2020.